It was a delight to discuss with Anna Moltó (Hospital Cochin, Paris, France) the results of the TICOSPA trial (NCT03043846) which was designed to evaluate the benefit of treat-to-target in patients with axial spondyloarthritis.
The abstract entitled ‘Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The Results of the TICOSPA Trial’ (ABSTRACT NUMBER: 1444) was presented at the 2020 ACR Convergence, 5-9 November.
- What are the arguments for and against the treat-to-target (T2T) strategy in the management of axial spondyloarthritis? (0:05)
- Could you tell us a little about the design of the TICOSPA trial? (1:51)
- What were the findings of this study in terms of primary outcomes and safety of the T2T strategy? (2:55)
- What are the implications of these findings for clinical practice? (4:10)
Disclosures: Anna Moltó has acted as a Consultant/Speaker for Abbvie, BMS, Eli Lilly, Novartis, UCB and Gilead.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Axial Spondyloarthritis
Axial spondyloarthritis treatment paradigm and unmet needs: Fabian Proft, EULAR 2023
Axial spondyloarthritis is a chronic, inflammatory rheumatic disease that affects the axial skeleton, causing severe pain, stiffness and fatigue. touchIMMUNOLOGY were delighted to speak with Dr Fabian Proft (Charité Universitätsmedizin Berlin, Germany) about the treatment paradigm and unmet needs of axial spondyloarthritis. The abstract ‘Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with […]
BE MOBILE 1 and BE MOBILE 2: phase 3 studies of bimekizumab in axial spondyloarthritis: Fabian Proft, EULAR 2023
BE MOBILE 1 and BE MOBILE 2 are double-blind, phase 3 trials designed to evaluate efficacy and safety of bimekizumab, a novel dual interleukin (IL)-17A and IL-17F inhibitor, across the axial spondyloarthritis spectrum. touchIMMUNOLOGY were delighted to speak with Dr Fabian Proft (Charité Universitätsmedizin Berlin, Germany) about these trials and his poster on the maintenance […]
Xenofon Baraliakos, ACR 2022: Bimekizumab in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis – 52 week findings from BE MOBILE 1 and 2
Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits both IL-17F and IL‑17A, was recently investigated in the phase 3 BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743) clinical trials for active non-radiographic axial spondyloarthritis and ankylosing spondylitis, respectively. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany) to discuss […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!